Introduction: Donohue's syndrome, also known as Leprechaunism, is a rare autosomal recessive disease that manifests at birth with symptoms of endocrine dysfunction. Metabolic characteristics of the disease include postprandial hyperglycemia, fasting hypoglycemia, insulin resistance, hyperinsulinemia, and failure to thrive. The physical features most often associated with this condition include hypertrichosis, pachyderma, acanthosis nigricans, prominent genitalia, and elfin-like facial characteristics of prominent eyes, wide nostrils, thick lips, and large, low-set ears. Not only is this syndrome rare, but it often results in infant and early childhood mortality. The literature regarding ocular manifestations is limited.

Case Report: We present a case of a 29-year-old male with Donohue's syndrome and significant ocular findings including a subluxated mature cataract, retinal detachment, high myopia, and optic atrophy.

Discussion: These ocular sequelae are discussed with regard to the noted endocrine dysfunction and its effects on tissue development and growth.

Download full-text PDF

Source
http://dx.doi.org/10.1097/00006324-200305000-00008DOI Listing

Publication Analysis

Top Keywords

donohue's syndrome
12
ocular manifestations
8
endocrine dysfunction
8
ocular
4
manifestations donohue's
4
syndrome
4
syndrome introduction
4
introduction donohue's
4
syndrome leprechaunism
4
leprechaunism rare
4

Similar Publications

Importance: A substantial number of individuals worldwide experience long COVID, or post-COVID condition. Other postviral and autoimmune conditions have a female predominance, but whether the same is true for long COVID, especially within different subgroups, is uncertain.

Objective: To evaluate sex differences in the risk of developing long COVID among adults with SARS-CoV-2 infection.

View Article and Find Full Text PDF

Introduction: Congenital Hyperinsulinism (CHI) has not been previously studied in Ukraine. We therefore aimed to elucidate the genetics, clinical phenotype, histological subtype, treatment and long-term outcomes of Ukrainian patients with CHI.

Methods: Forty-one patients with CHI were recruited to the Ukrainian national registry between the years 2014-2023.

View Article and Find Full Text PDF

Association between buprenorphine dose and outcomes among pregnant persons with opioid use disorder.

Am J Obstet Gynecol

December 2024

Magee-Womens Research Institute, Pittsburgh, PA; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA.

Background: Opioid use disorder contributes to maternal morbidity and mortality in the United States. Little is known about how the patterns of buprenorphine dose and duration throughout pregnancy may affect neonatal and postpartum outcomes.

Objective: To determine the associations between trajectories of buprenorphine utilization and dose during pregnancy on maternal and neonatal health outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Iliofemoral deep venous thrombosis is linked to post-thrombotic syndrome (PTS), and two main treatments are pharmacomechanical catheter-directed thrombolysis (PCDT) and mechanical thrombectomy (MT) with large-bore devices.
  • A study analyzed 349 patients from 2007 to 2022, comparing PCDT and MT, focusing on PTS rates, vessel patency, and other outcomes, finding no significant differences in PTS rates between the two treatment groups.
  • MT patients had better logistical outcomes, including greater likelihood of a single operating room visit and shorter ICU stay, but it was not associated with increased PTS risk or higher Villalta scores.
View Article and Find Full Text PDF

Introduction: A clear immune correlate of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has not been defined. We explored antibody, B-cell, and T-cell responses to the third-dose vaccine and relationship to incident SARS-CoV-2 infection.

Methods: Adults in a prospective cohort provided blood samples at day 0, day 14, and 10 months after the third-dose SARS-CoV-2 vaccine.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!